NIR activated upconversion based nanocatalysts for CT/PA imaging-guided triple synergistic PTT/PDT/CDT cancer treatment

Abstract

Photodynamic therapy (PDT), as a non-invasive treatment, is expected to be widely used in clinical cancer treatment. In this paper, a near-infrared (NIR) light responsive Lu2O3:Yb/Er/Li-Ce6@MIL-101/GOx-PDA (LCMGP) nanodiagnostic platform was prepared for CT/PA imaging-guided multimodality synergistic therapy. Under 808 nm laser irradiation, Lu2O3:Yb/Er/Li-Ce6 (LC) NPs in the nano-diagnostic platform are activated and sensitized by NIR light, resulting in the generation of more single-linear oxygen (1O2) for efficient PDT. Glucose oxidase (GOx) and MIL-101 (Fe) nanozymes can utilize their excellent enzyme cascade catalytic properties and peroxidase-like catalytic properties to undergo glycolysis reactions and catalyze the decomposition of endogenous hydrogen peroxide (H2O2), producing a large amount of hydroxyl radicals (•OH), achieving efficient chemodynamic therapy (CDT). The functionalized modification of polydopamine (PDA) endows the LCMGP nanoparticles with higher photothermal conversion efficiency, which can prompt high local temperature at the tumor site under the irradiation of NIR light to achieve efficient photothermal therapy (PTT). In addition, hyperthermia accelerates the catalytic efficiency of the nanozymatic cascade of LCMGP nanoparticles to enhance ROS production while increasing cellular uptake, resulting in PTT-induced PDT/CDT synergistic effect (96%). Based on the excellent photothermal conversion effect of PDA and the high X-ray attenuation effect of Lu/Fe, the LCMGP nanotherapeutic system demonstrates good CT/PA imaging function, providing new insights and ideas for imaging-mediated multimodal synergistic therapy.